期刊文献+

反相高效液相色谱法测定利卡西平血药浓度 被引量:4

The determination of licarbazepine concentration in patients' plasma by RP-HPLC
下载PDF
导出
摘要 目的:建立利卡西平血药浓度测定方法。方法:采用反相高效液相色谱法,色谱柱:Waters sunfire C_(18)柱(4.6 mm×250 mm,5μm);流动相:甲醇-水-三氟乙酸(600:400:0.5);流速:1.0 mL·min^(-1);柱温:40℃;检测波长:230 nm;进样量:20μL。内标物:盐酸赛庚啶。结果:以利卡西平与内标物峰面积之比(y)对利卡西平血清浓度(C)进行线性回归,得回归方程:C=1.227×10~2 y–0.364(r^2=0.999 6,n=7),结果表明利卡西平在5.0~100.0μg·mL^(-1)范围内样品回收率高(平均回收率为99.80%,RSD=1.25%)。结论:本方法操作简便、精密度好,可用于利卡西平的治疗药物监测。 Objective:To set up the HPLC method for determination of licarbazepine concentration in patient's plasma.Methods:The residues were analyzed by RP-HPLC method.Waters sunfire C18 column(4.6 mm × 250 mm,5 μm) was used,methanol-water-trifluoroacetic acid(600 :400 :0.5) was used as mobile phase.The flow rate was 1.0 mL·min^-1.The detection wavelength was set at 230 nm and the column temperature was 40 ℃.The sample size was 20 μL.Cyproheptadine hydrochloride was used as internal standard.Results:Linear regression analysis was made by licarbazepine serum concentration(C) and the peak area ratio(y) of licarbazepine vs internal standard.The regression equation was C = 1.227 × 10^2 y-0.364(r^2 = 0.999 6,n = 7).The results showed that the recovery ratio of licarbazepine was high in the range of 5.0-100.0 μg·mL^-1(average recovery rate = 99.80%,RSD = 1.25%).Conclusion:The method provided a simple and precise way for monitoring plasma concentration level of licarbazepine,and this method can be used for therapeutic drug monitoring of licarbazepine.
出处 《中国药物应用与监测》 CAS 2017年第5期267-270,共4页 Chinese Journal of Drug Application and Monitoring
关键词 利卡西平 反相高效液相色谱法 血药浓度 治疗药物监测 Licarbazepine RP-HPLC Blood drug concentration Therapeutic drug monitoring
  • 相关文献

参考文献4

二级参考文献57

  • 1付琳,邱相君,代宗顺,侯淑贤,庞雪冰,吴怀安.奥卡西平片的人体相对生物利用度研究[J].中国药科大学学报,2004,35(3):244-247. 被引量:18
  • 2张军,刘玉才.奥卡西平的药理与临床[J].国外医药(合成药.生化药.制剂分册),1995,16(2):93-95. 被引量:5
  • 3邓本强,王静华,丁素菊,吴涛.奥卡西平治疗成人癫的疗效和安全性观察[J].第二军医大学学报,2007,28(2):218-219. 被引量:6
  • 4Susan MG,Diana Faulds.Oxcarbazepine A Review of its Pharmacology and Therapeutic Potential in Epilepsy, Trigeminal Neuralgia and Affective Disorders[J].Drugs,1992,43(6):873-888.
  • 5Dickinson RG,Hooper WD,Dunstan PR,et al.First dose and steady-state pharmacokintics of oxcarbazepine and its 10-hydroxy metabolite [J].Eur J Clin Pharmacol,1989,37:69-74.
  • 6PüBlau, WD Paar,GE von Unruh.Pharmacokintics of oxcarbazepine and 10-hydroxy-carvazepine in the newborn child of an oxcarbazepine-treated mother[J].Eur J Clin Pharmacol,1988,34:311-313.
  • 7中华人民共和国药典2000年版.(二部)[S].2000:附录193-197.
  • 8Philip N,Patsalos,Josemir W,et al.Newer antiepileptic drugs[J].Drugs Safety,1994,11(1):37-67.
  • 9Rouan MC,Lecaillon JB,Godbillon J.The effect of renal impairment on the pharmacokinetics of oxcabazepine and its metablites[J].Eur J Clin Pharmacol,1994,47:161-167.
  • 10Lioyd P,Flesch G,Dieterle W.Clinical pharmacology and pharmacokinetics of oxcarbazepine[J].Epilepsia,1994,35(3):10-13.

共引文献38

同被引文献18

引证文献4

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部